Biokangtai

1 known investors

Biokangtai develops and manufactures human vaccines, including a 13-valent pneumococcal polysaccharide conjugate vaccine, a four-dose freeze-dried human rabies vaccine (human diploid cell), a combined acellular DTP–Hib vaccine, and a 60µg hepatitis B vaccine.

BiotechHealthtech